ROLE OF CYTOCHROME P4502E1 IN ALCOHOLIC LIVER-DISEASE PATHOGENESIS

被引:134
|
作者
MORIMOTO, M
HAGBJORK, AL
NANJI, AA
INGELMANSUNDBERG, M
LINDROS, KO
FU, PC
ALBANO, E
FRENCH, SW
机构
[1] UCLA,HARBOR MED CTR,DEPT PATHOL,TORRANCE,CA 90509
[2] KAROLINSKA INST,DEPT PHYSIOL CHEM,S-10401 STOCKHOLM,SWEDEN
[3] NEW ENGLAND DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02215
[4] HARVARD UNIV,SCH MED,BOSTON,MA
[5] STATE ALCOHOL MONOPOLY,RES LABS,HELSINKI,FINLAND
[6] UNIV TORINO,DEPT EXPTL MED & ONCOL,TURIN,ITALY
关键词
ALD MODEL; LIPID PEROXIDATION; PUFA; FATTY ACID; LINOLEIC ACID; PROTEIN ADDUCTS; DIALLYL SULFIDE; CYTOCHROME P4502E1;
D O I
10.1016/0741-8329(93)90065-V
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The intragastric tube feeding model is ideal for the study of the role of dietary factors and the effect of drugs on experimental alcoholic liver disease (ALD), since the model allows us to study the effect of a single variable in the diet on the pathology of liver where the blood alcohol level (BAL) is maintained over 150 mg%. By varying the dietary fatty acid composition we showed that the pathology was worsened by increasing linoleic acid or polyunsaturated fatty acids (PUFAs) in the diet where cytochrome P4502E1 (CYP2E1) was increased posttranslationally by high BAL. Concomitant with the increase in CYP2E1 there was evidence for an increase in lipid peroxidation (LP) by microsomes. Protein adducts of the products of LP were increased in the blood. Isoniazid (INH) enhanced this process and the pathology of ALD when INH was fed at therapeutic levels with ethanol. Preliminary studies show that diallyl sulfide, which inhibits and destroys liver CYP2E1 selectively, also modified the pathologic effects of ethanol. Thus we postulate that CYP2E1 induction plays a central role in the pathogenesis of ALD.
引用
收藏
页码:459 / 464
页数:6
相关论文
共 50 条
  • [31] Expression of cytochrome P4502E1 gene in hepatocellular carcinoma
    Xiao-Bo Man Liang Tang Xiu-Hua Qiu Hni-Fang Cao Hong-Yang Wang International Co-operation Laboratory on Signal Transduction
    World Journal of Gastroenterology, 2004, (11) : 1565 - 1568
  • [32] Covalent binding and inhibition of cytochrome P4502E1 by trichloroethylene
    Halmes, NC
    Samokyszyn, VM
    Pumford, NR
    XENOBIOTICA, 1997, 27 (01) : 101 - 110
  • [33] Expression of cytochrome P4502E1 gene in hepatocellular carcinoma
    Man, Xiao-Bo
    Tang, Liang
    Qiu, Xiu-Hua
    Yang, Li-Qun
    Cao, Hui-Fang
    Wu, Meng-Chao
    Wang, Hong-Yang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (11) : 1565 - 1568
  • [34] CYTOCHROME P4502E1 (CYP2E1) GENETIC-POLYMORPHISM IN A CASE-CONTROL STUDY OF GASTRIC-CANCER AND LIVER-DISEASE
    KATO, S
    ONDA, M
    MATSUKURA, N
    TOKUNAGA, A
    TAJIRI, T
    KIM, DY
    TSURUTA, H
    MATSUDA, N
    YAMASHITA, K
    SHIELDS, PG
    PHARMACOGENETICS, 1995, 5 : S141 - S144
  • [35] Hepatic metabolism of skatole in pigs by cytochrome P4502E1
    Babol, J
    Squires, J
    Lundström, K
    JOURNAL OF ANIMAL SCIENCE, 1998, 76 (03) : 822 - 828
  • [36] Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice
    Lu, Yongke
    Wu, Defeng
    Wang, Xiaodong
    Ward, Stephen C.
    Cederbaum, Arthur I.
    FREE RADICAL BIOLOGY AND MEDICINE, 2010, 49 (09) : 1406 - 1416
  • [37] Cytochrome P4502E1 genotypes, alcoholism, and alcoholic cirrhosis in Han Chinese and Atayal natives of Taiwan
    Carr, LG
    Yi, IS
    Li, TK
    Yin, SJ
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1996, 20 (01) : 43 - 46
  • [38] ROLE OF ACETALDEHYDE IN THE PATHOGENESIS OF ALCOHOLIC LIVER-DISEASE
    PETERS, TJ
    WARD, RJ
    MOLECULAR ASPECTS OF MEDICINE, 1988, 10 (02) : 179 - 190
  • [39] ROLE OF ACETALDEHYDE IN THE PATHOGENESIS OF ALCOHOLIC LIVER-DISEASE
    BARRY, RE
    BRITISH JOURNAL OF ADDICTION, 1988, 83 (12): : 1381 - 1386
  • [40] The mechanism of the rat liver cytochrome P4502E1 inhibition by the synthetic prostanoids of A-type
    Hubich, A. I.
    Lakhvich, F. A.
    Sholukh, M. V.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2009, 89 (1-2) : 16 - 19